MRKR Marker Therapeutics, Inc.: ערך חשבונאי של החברה

The following quotes for Marker Therapeutics (MRKR) reflect the performance of a company developing a unique T-cell system to combat hematological pathologies, ensuring long-term patent protection and a steady cash flow. The business focuses on developing non-gene-edited cellular methods for treating various tumors, thereby reducing therapy toxicity. The current metric stands at 0.01, while sales potential remains immense due to the shortage of medications in specialized clinics.

To objectively measure the operational success of Marker Therapeutics (MRKR), it is essential for investors to track the real value of net assets adjusted for debt. The trajectory of the company's book capitalization reflects the daily dynamics of equity, which is critical for financing the development of the mtcTAA platform and navigating clinical phases to expand into the oncohematology segment over the long term.